

09MD
K26

**THE EFFECT OF CYTOTOXIC CHEMOTHERAPY ON
THE MUCOSA OF THE SMALL INTESTINE**



by

Dorothy Mary Kate Keefe

M.B. B.S, F.R.A.C.P.

JUNE 1998

Thesis submitted for the degree of

Doctor of Medicine

within the Faculty of Medicine

The University of Adelaide

Departments of Gastroenterology

and Haematology/Oncology

The Queen Elizabeth Hospital

Woodville South, South Australia

TABLE OF CONTENTS

Table of Contents	i
Abstract	viii
Declaration	xi
Acknowledgments	xii
Abbreviations	xiii

Chapter 1 Introduction and Hypothesis

1.1	Introduction	1
1.2	Definition of mucositis	2
1.3	Hypothesis	2
1.4	Aims	3
1.5	Research Plan	4

Chapter 2 Review of the Literature Concerning Chemotherapy, the Small Intestine and Mucositis

2.1	Principles of the action of chemotherapy on tumours	5
2.2	Overview of the side effects of chemotherapy	6
2.3	Mucositis	7

2.4	Gastrointestinal side effects of chemotherapy	8
2.5	Small intestinal morphology and function	9
2.6	Assessment of the structure and function of the small intestine	14
2.61	Historical	14
2.62	Current 'state of the art' assessment	14
2.62.1	Direct	14
2.62.2	Indirect assessment of the small intestine	15
2.62.3	Duodenal disaccharidases	16
2.62.4	Intestinal permeability	16
2.62.5	Breath testing to assess bacterial overgrowth and oro-caecal transit time	18
2.63	Animal <i>versus</i> human	18
2.7	Nutrition and malignancy	19
2.8	Immunology of the gastrointestinal tract and nutrition.....	21
2.9	Response of the small intestine to injury	21
2.10	Apoptosis <i>versus</i> necrosis	22
2.11	Comparison with Coeliac disease	24
2.12	Bacterial translocation	25
2.13	Stem cells and regeneration of intestinal crypts after cytotoxic exposure	26
2.14	Effects of irradiation on the small intestine	26
2.15	Structure of the small intestinal mucosa following chemotherapy.....	28
2.16	Histology of the small intestine following chemotherapy.....	31
2.17	Oral chemotherapy	38
2.18	Dose of chemotherapy and crypt survival	39

2.19	Bone marrow transplantation and the small intestine	39
2.20	Irinotecan: A special case?	41
2.21	Functional changes in the small intestine following chemotherapy	42
2.22	The effect of chemotherapy on small intestinal permeability	45
2.23	Treatment of chemotherapy-induced small intestinal damage	48
2.24	Trials of oral and small intestinal mucositis prevention	51
2.24.1	Glutamine	51
2.24.2	Transforming growth factor β	53
2.24.3	Interleukin-11	55
2.24.4	Keratinocyte growth factor.....	57
2.24.5	GM-CSF and G-CSF	57
2.24.6	Whey growth factor extract	58
2.24.7	Total parenteral nutrition	58
2.24.8	Other special dietary modifications	59
2.24.9	Epidermal growth factor	62
2.24.10	Growth hormone and IGF-1	62
2.24.11	Other potential agents to prevent or treat mucositis	62
2.24.12	Combinations of growth factors to prevent mucositis	66
2.25	Safety issues in mucositis prevention	67
2.26	Summary	68

Chapter 3 The Effect of High Dose Chemotherapy and Autologous Stem Cell Transplantation on Small Intestinal Permeability in Humans

3.1	Introduction	69
3.2	Methodology	72
3.3	Results	76
3.4	Discussion	82

Chapter 4 An investigation into abdominal and oral symptoms and small intestinal function following cytotoxic chemotherapy

4.1	Introduction	85
4.2	Methodology	86
4.21	Assessment of nutrition and symptoms	89
4.22	Intestinal sugar permeability test	94
4.23	Endotoxin assay	95
4.24	Breath testing: combined lactulose breath hydrogen and ¹⁴ C-D-xylose breath test	96
4.24.1	Test principles	97
4.24.2	Methodology	98
4.24.3	Result analysis	99
4.25	Statistical analysis	100

4.3	Results	102
4.30	Demographics	102
4.31	Nutrition and symptoms	105
4.32	Intestinal sugar permeability	128
4.33	Serum endotoxin	132
4.34	Assessment of bacterial overgrowth	132
4.4	Discussion	134

Chapter 5 Small Intestinal Morphological Changes after Chemotherapy

5.1	Introduction	140
5.2	Methodology	142
5.21	Disaccharidases	142
5.22	Light microscopy	143
5.23	Electron microscopy	145
5.24	Statistics	146
5.3	Results	
5.31	Disaccharidases	147
5.32	Light microscopy	147
5.33	Electron microscopy	157
5.4	Discussion	162
5.5	Summary	164

**Chapter 6 Development of the Dark Agouti Rat Mammary Adenocarcinoma Model
to Assess Small Intestinal and Tumour Effects of Chemoprevention**

6.1	General introduction	166
6.2	A study to find the optimum dose of methotrexate to cause non-lethal small intestinal mucositis in the dark agouti rat	168
6.21	Introduction	168
6.22	Methodology	169
6.23	Results	170
6.24	Discussion	175
6.3	The effect of glutamine in preventing small intestinal mucositis in the dark agouti rat mammary adenocarcinoma model	176
6.31	Introduction	176
6.32	Methodology	176
6.33	Results	181
6.34	Discussion	196
Chapter 7	Summary and Conclusions	197

Appendix (I)	Breath Test Result Examples	201
Appendix (II)	Chemotherapy Drug Regimens Used	203
Appendix (III)	Toxicity Grades	207
Bibliography	210
Publications arising from this thesis		235

Abstract

This thesis investigated the effect of chemotherapy on the mucosa of the small intestine both in humans and in rats.

Introduction: Mucositis after chemotherapy for cancer is becoming increasingly important, both as a cause of patient morbidity and occasional mortality, and because the resulting toxicity potentially limits the dose, and therefore the chance of cancer cure. The reasons for mucositis becoming more predominant are two-fold; protection from bone marrow toxicity by colony stimulating factors has led to increased doses of drugs being given, and there is a drive to increase doses in order to increase cure rate. The aims of the project were to investigate the prevalence, duration and severity of mucositis in the gastrointestinal tract following chemotherapy.

Literature review: this covers the areas of mucositis, small intestinal morphology, apoptosis, nutrition and malignancy, intestinal sugar permeability, and the effects of chemotherapy on the small intestine. Most chemotherapeutic agents kill rapidly dividing cells, making the gastrointestinal tract particularly vulnerable. Cytotoxic agents kill cells at different levels of the crypt hierarchy, leading to crypt hypoplasia followed by regeneration. The exact mechanism of mucositis is not known, nor is it apparent if there are functional abnormalities of absorption, and how these correlate with symptoms such as bloating, abdominal pain and diarrhoea.

Research plan: the project is split into four areas:

1. Mucositis was studied after high dose chemotherapy and autologous blood stem cell transplantation in forty patients. Symptoms were recorded and mucositis assessed indirectly by an intestinal sugar permeability test. Oral mucositis occurred in 100% of patients, with 50% having grade 3 or 4 oral mucositis. Small intestinal symptoms (diarrhoea, vomiting) of grade 3 or 4 occurred in 41%, permeability peaking at an increase over baseline value of 6.8-fold at day 14. The conclusion from this study was that high dose chemotherapy causes a transient increase in intestinal permeability associated with small intestinal symptoms.

2. A second study was undertaken of small intestinal mucositis after both standard and high-dose chemotherapy, to further define the prevalence, duration and symptom severity at intervals of 3 days up to 14 days, and then at 28 days after chemotherapy. Symptoms were scored by questionnaire, and mucositis was assessed by an iso-osmolar sugar permeability test. Nutritional changes were small. Serum endotoxin and combined breath tests for bacterial overgrowth were unhelpful.

3. A third study assessed small intestinal mucosal histology following chemotherapy. Morphological changes began with a transient increase in crypt apoptosis at day 1 after chemotherapy, followed by a reduction in villus area, crypt length and mitotic index by day 3, the latter two rebounding to greater than baseline levels at day 16. Thus the new finding of this study was that mucositis is due to induction of early crypt apoptosis that precedes hypoplastic villous atrophy.

4. The effect of oral glutamine on ameliorating intestinal mucositis was assessed in the dark agouti (DA) rat given subcutaneous implants of isogeneic mammary adenocarcinoma and treated with methotrexate (MTX). Glutamine had no significant effect on tumour growth, nor did it ameliorate mucositis as assessed by apoptosis and villus area, crypt length and mitotic count. The conclusions were that this is a good model for further study of mucositis, and that glutamine does not protect against small intestinal mucositis.

Conclusions: The conclusion of this thesis is that small intestinal mucositis occurs symptomatically in a significant number of patients, and peaks 3-7 days after treatment. The principal mechanism is apoptosis of intestinal crypts that results in intestinal hypoplasia.